Commentary: Clinical Use of SGLT2 Inhibitors, GLP-1RA, and Insulin, September 2022September 6, 2022Diabetes
Prior gestational diabetes complicates long-term macrovascular outcomes in women with T2DAugust 31, 2022Diabetes
Increasing empagliflozin dose benefits T2D patients with inadequate glycemic controlAugust 31, 2022Diabetes
T2D: Dapagliflozin consistently reduces CV and kidney disease risk irrespective of background therapyAugust 31, 2022Diabetes
T2D: No evidence to suggest increased fracture risk with DPP-4i, GLP-1 RA, and SGLT-2iAugust 31, 2022Diabetes
